Abstract Details

Title SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-up Experience for Patients with OSA in Germany

Topic Sleep

Presentation(s) P9 - Poster Session 9 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-010

Objective To characterize real-world dosing/titration strategies among German physicians initiating solriamfetol and patient outcomes following initiation.

Background Excessive daytime sleepiness (EDS) is a symptom of obstructive sleep apnea (OSA) that can persist despite efficacious suppression of apnea via primary airway therapy (PAT) and can be managed with wake-promoting agents, including solriamfetol, an approved treatment for EDS associated with OSA.

Design/Methods SURWEY was a retrospective chart review conducted by German physicians. German patients (n=83) diagnosed with EDS due to OSA, had reached a stable solriamfetol dose, and had completed ≥6 weeks of treatment were included. Patients were classified based on solriamfetol initiation strategy: 1) changeover (switched from existing EDS medication[s]), 2) add-on (added to current EDS medication[s]), or 3) new-to-therapy (no current EDS medication). Efficacy measures included the Epworth Sleepiness Scale (ESS) and patient- and physician-reported perceptions of improvement.

Results All patients (mean age=49 years; 65% male) used PAT. The most common initiation type was new-to-therapy (n=62), followed by add-on (n=12), and changeover (n=9). The most common starting doses of solriamfetol were 37.5 (n=57;69%) and 75 (n=23;28%) mg/day. Solriamfetol was titrated in 53 patients (64%); often within 7 days. Mean±SD ESS score was 16.0±3.2 (n=83) at initiation and 10.7±3.9 at follow-up (n=83; mean ESS decrease= 5.4±3.6). Across subgroups, mean ESS scores ranged from 15.9–16.6 (initiation) and 10.4-12.2 (follow-up), with mean decreases from 5.3–5.7 points. Improvement rates in EDS after solriamfetol initiation were patient-reported, 90%; physician-reported, 89%. Most patients reported solriamfetol effects lasted ≥6 hours (74%) without altering night-time sleep quality (91%). Common adverse effects were headache, insomnia, and irritability.

Conclusions In this real-world data from a cohort of German patients with OSA, solriamfetol was typically initiated at 37.5 mg/day and titration was common. ESS improvements were clinically meaningful, and most patients and physicians perceived improvement in EDS. No new safety signals were reported.

Authors/Disclosures
Samantha Floam, DMD (Axsome Therapeutics) PRESENTER	Dr. Floam has received personal compensation for serving as an employee of Axsome Therapeutics.
Yaroslav Winter	Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini Pharma. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bioprojet. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia Pharmaceuticals. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for JAZZ Pharmaceuticals. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Presisis.
Geert K. Mayer, MD, PhD (Philipps-Universität Marburg)	Dr. Mayer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen, Idorsia, NLS Pharma. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia, Takeda. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Idorsia.
Heike Benes	No disclosure on file
Lothar Burghaus	No disclosure on file
Iresha Abeynayake	Iresha Abeynayake has received personal compensation for serving as an employee of Axsome. Iresha Abeynayake has stock in Axsome.
Hannah Kwak	No disclosure on file
Gregory S. Parks, PhD (Axsome Therapeutics)	Dr. Parks has received personal compensation for serving as an employee of Axsome Therapeutics. Dr. Parks has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Parks has stock in Axsome Therapeutics. Dr. Parks has stock in Jazz Pharmaceuticals.
Ulf Kallweit	Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bioprojet. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bioprojet. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bioprojet. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmanovia. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier.

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details